Sector
PharmaceuticalsOpen
₹375.45Prev. Close
₹373.1Turnover(Lac.)
₹434.61Day's High
₹376.2Day's Low
₹369.952 Week's High
₹57152 Week's Low
₹325.3Book Value
₹58.69Face Value
₹2Mkt Cap (₹ Cr.)
4,178.74P/E
37.95EPS
9.82Divi. Yield
1.37Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 22.37 | 22.37 | 22.36 | 22.35 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 558.11 | 502.97 | 457.99 | 413.1 |
Net Worth | 580.48 | 525.34 | 480.35 | 435.45 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 272.79 | 283.47 | 247.35 | |
yoy growth (%) | -3.76 | 14.6 | ||
Raw materials | -99.2 | -96.3 | -88.75 | |
As % of sales | 36.36 | 33.97 | 35.88 | |
Employee costs | -39.31 | -34.23 | -32.6 | -32.48 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 72.07 | 98.42 | 75.85 | |
Depreciation | -9.56 | -9 | -8.81 | -7.81 |
Tax paid | -17.56 | -27.41 | -17.89 | |
Working capital | 37.12 | -10.33 | 26.58 | -6.36 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -3.76 | 14.6 | ||
Op profit growth | -27.86 | 31.19 | ||
EBIT growth | -26.75 | 28.03 | ||
Net profit growth | -23.23 | 22.52 | 61.47 | 3.81 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 623.87 | 540.64 | 529.38 | 501.84 | 443.99 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 623.87 | 540.64 | 529.38 | 501.84 | 443.99 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 36.66 | 25.46 | 6.42 | 8.85 | 5.64 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,800.05 | 156.54 | 4,31,544.39 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,210.55 | 89.74 | 1,64,865.28 | 518 | 0.48 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,533.9 | 29.27 | 1,23,920.06 | 1,178.16 | 0.85 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,363.1 | 69.54 | 1,13,766.71 | 460 | 0.83 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,559 | 51.15 | 1,02,527.44 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time director
MUKUND MADHUSUDAN KABRA
Chairman (Non-Executive)
VASANT RATHI
Independent Director
Pramod Kasat
Company Sec. & Compli. Officer
Sanjay Basantani
Non-Exec & Non-Independent Dir
Rasika Rathi
Independent Director
Vindokumar Hiralal Jajoo
Non-Exec & Non-Independent Dir
Sunny Sharma
Independent Director
Rajshree Patel
Independent Director
NITIN JAGANNATH DESHMUKH
Independent Director
Vandana Tilak.
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Advanced Enzyme Technologies Ltd
Summary
Advanced Enzyme Technologies Limited (AETL) is largest Indian enzyme company that has transformed business globally in the manufacturing and sale of enzymes. Advanced Enzyme Technologies Limited was incorporated, as a Private Company on March 15, 1989 as Advanced Biochemicals Private Limited in Maharashtra. The Company thereafter, got converted into a Public Company and the name of the Company changed to Advanced Biochemicals Limited on May 28, 1992. Again, the name was changed to Advanced Enzyme Technologies Limited and a fresh Certificate of Incorporation was issued by the Registrar of Companies, Mumbai on August 19, 2005.In 2011, the company took over Cal-India Foods International, giving the company direct presence in USA.In 2012, the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA.Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4,594,875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees), consisting of fresh issue of 560,405 Equity shares and an Offer for Sale of 4,034,470 Equity shares by Selling Shareholders. The IPO was open for subscription during the period from 20 July 2016 to 22 July 2016. The said offer was overall subscribed 82.06 times. The equity shares of Advanced Enzyme Technologies Limited were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 1 August 2016 at an
Read More
The Advanced Enzyme Technologies Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹373.5 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Advanced Enzyme Technologies Ltd is ₹4178.74 Cr. as of 04 Dec ‘24
The PE and PB ratios of Advanced Enzyme Technologies Ltd is 37.95 and 6.92 as of 04 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Advanced Enzyme Technologies Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Advanced Enzyme Technologies Ltd is ₹325.3 and ₹571 as of 04 Dec ‘24
Advanced Enzyme Technologies Ltd's CAGR for 5 Years at 17.69%, 3 Years at 3.82%, 1 Year at 13.80%, 6 Month at 3.62%, 3 Month at -15.89% and 1 Month at -21.86%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice